DE602004024383D1 - Kristalline formen eines arylanilin-beta-2-adrenergenrezeptor-agonists - Google Patents

Kristalline formen eines arylanilin-beta-2-adrenergenrezeptor-agonists

Info

Publication number
DE602004024383D1
DE602004024383D1 DE602004024383T DE602004024383T DE602004024383D1 DE 602004024383 D1 DE602004024383 D1 DE 602004024383D1 DE 602004024383 T DE602004024383 T DE 602004024383T DE 602004024383 T DE602004024383 T DE 602004024383T DE 602004024383 D1 DE602004024383 D1 DE 602004024383D1
Authority
DE
Germany
Prior art keywords
beta
sub
arylanilin
adreneer
receptor agonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602004024383T
Other languages
German (de)
English (en)
Inventor
Sabine Axt
Ioanna Stergiades
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innoviva Inc
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of DE602004024383D1 publication Critical patent/DE602004024383D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE602004024383T 2003-05-08 2004-05-07 Kristalline formen eines arylanilin-beta-2-adrenergenrezeptor-agonists Expired - Fee Related DE602004024383D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46881003P 2003-05-08 2003-05-08
PCT/US2004/014302 WO2004101525A1 (en) 2003-05-08 2004-05-07 Crystalline form of aryl aniline beta-2 adrenergic receptor agonist

Publications (1)

Publication Number Publication Date
DE602004024383D1 true DE602004024383D1 (de) 2010-01-14

Family

ID=33452233

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004024383T Expired - Fee Related DE602004024383D1 (de) 2003-05-08 2004-05-07 Kristalline formen eines arylanilin-beta-2-adrenergenrezeptor-agonists

Country Status (6)

Country Link
US (1) US7060712B2 (https=)
EP (1) EP1622875B1 (https=)
JP (1) JP2006528242A (https=)
AT (1) ATE450511T1 (https=)
DE (1) DE602004024383D1 (https=)
WO (1) WO2004101525A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653323B2 (en) * 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
US20030229058A1 (en) * 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
PE20050130A1 (es) * 2002-08-09 2005-03-29 Novartis Ag Compuestos organicos
TW200526547A (en) * 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
TW200531692A (en) * 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
EP1786762A2 (en) * 2004-09-10 2007-05-23 Theravance, Inc. Amidine substituted aryl aniline compounds
GB0426164D0 (en) * 2004-11-29 2004-12-29 Novartis Ag Organic compounds
AU2006205933A1 (en) * 2005-01-11 2006-07-20 Glaxo Group Limited Cinnamate salts of a beta-2 adrenergic agonist
GB0512246D0 (en) * 2005-06-15 2005-07-27 Glaxo Group Ltd Novel pharmaceutical
TW200811104A (en) * 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound
GB0613154D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
TW200840578A (en) * 2006-12-15 2008-10-16 Procter & Gamble Compositions of azimilide dihydrochloride
US20120178762A1 (en) 2006-12-15 2012-07-12 Warner Chilcott Company, Llc Compositions of azimilide dihydrochloride
ES2320961B1 (es) * 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
CN103547575B (zh) 2011-06-10 2016-08-17 奇斯药制品公司 具有毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂活性的化合物
AU2013259872B2 (en) 2012-05-08 2018-06-28 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894219A (en) * 1988-03-29 1990-01-16 University Of Florida Beta-agonist carbostyril derivatives, assay method and pharmacological composition
GB9713819D0 (en) * 1997-06-30 1997-09-03 Glaxo Group Ltd Method of reducing the systemic effects of compounds
OA11558A (en) * 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
EP1366025B1 (en) 2001-03-08 2007-06-27 Glaxo Group Limited Agonists of beta-adrenoreceptors
JP4143413B2 (ja) 2001-03-22 2008-09-03 グラクソ グループ リミテッド β２−アドレナリン受容体アゴニストとしてのホルムアニリド誘導体
ES2438985T3 (es) 2001-09-14 2014-01-21 Glaxo Group Limited Formulación de inhalación que comprende derivados de fenetanolamina para el tratamiento de enfermedades respiratorias
TWI249515B (en) * 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
US6653323B2 (en) * 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
US20030229058A1 (en) * 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
AU2003222841A1 (en) 2002-04-25 2003-11-10 Glaxo Group Limited Phenethanolamine derivatives

Also Published As

Publication number Publication date
EP1622875B1 (en) 2009-12-02
EP1622875A1 (en) 2006-02-08
WO2004101525A1 (en) 2004-11-25
ATE450511T1 (de) 2009-12-15
US7060712B2 (en) 2006-06-13
US20040224982A1 (en) 2004-11-11
JP2006528242A (ja) 2006-12-14

Similar Documents

Publication Publication Date Title
DE602004024383D1 (de) Kristalline formen eines arylanilin-beta-2-adrenergenrezeptor-agonists
TW200510277A (en) Crystalline form of β2-adrenergic receptor agonist
MY138220A (en) ARYL ANILINE ß2 ADRENERGIC RECEPTOR AGONISTS
TW200531692A (en) Aryl aniline derivatives as β2 adrenergic receptor agonists
BRPI0511695A (pt) agonistas de receptor (beta)2 adrenérgico diamina
MA29088B1 (fr) Composes d'indazole-carboxamide.
BR0312975A (pt) Forma cristalina de agonista de receptor adrenérgico ß2
NO20074567L (no) Glucagonreseptorantagoniser, fremstilling og terapeutisk anvendelse
TW200517388A (en) Thiazole derivatives as cannabinoid receptor modulators
ATE447408T1 (de) Kombinationen aus einem arylanilin-beta-2- adrenozeptor-agonisten und einem corticosteroid
CY1110922T1 (el) Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις
NO20061737L (no) Aminosubstituerte erylamino B2 adrenergiske receptoragonister
BRPI0507791A (pt) compostos de indazol-carboxamida como agonistas do receptor 5-ht4
MX2007008614A (es) Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r).
DE602005019043D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
NO20076481L (no) Benzimidazol-karboksamidforbindelser som 5-HT4 receptorantagonister
DE602006015509D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
BRPI0410237A (pt) metil indóis e metil pirrolopiridinas como agonistas adrenérgicos alfa-1
BRPI0608392A2 (pt) compostos de quinolinona como agonistas do receptor 5-ht4
MY143574A (en) Carbamate compounds as 5-ht4 receptor agonists

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee